- Latest Posts
News and Trends 19 Apr 2023
Wound treatment boost from new color-changing dressing
A nanocellulose wound dressing that can reveal early signs of infection without interfering with the healing process has been developed by researchers at Linköping University, Sweden. The study, published in Materials Today Bio, is another step on the road to a new type of wound care. The skin is the largest organ of the human […]
In Depth 19 Apr 2023
How Vaccine Platforms Can Prepare Us for Future Pandemics
The COVID-19 pandemic exposed the weaknesses in our defenses. Vaccine platforms will be powerful tools for reacting faster to future pandemics. Multiple COVID-19 vaccines became available across the world to tackle the COVID-19 pandemic, signaling a historic moment for vaccine development due to the speed at which they were created. And with scientists believing that […]
News and Trends 19 Apr 2023
Forbion raises €1.35B to invest in life science companies
European life sciences venture capital firm Forbion has raised €1.35 billion ($1.5 billion) for its two newest funds, bringing the total of funds under management to €3 billion ($3.3 billion). Both funds exceeded the original target sizes and represent Forbion’s largest fundraising to date. The final close of the Forbion Ventures Fund VI has reached […]
News and Trends 19 Apr 2023
Nanocages developed to deliver small interfering RNAs
Small interfering RNAs (siRNAs) are novel therapeutics that can be used to treat a wide range of diseases. This has led to a growing demand for selective, efficient, and safe ways of delivering siRNA in cells. Now, in a cooperation between the universities of Amsterdam and Leiden in the Netherlands, researchers have developed dedicated molecular […]
Expert Advice 18 Apr 2023
Pharmacovigilance – how to deal with the data
By Axel Hagel, practice leader, PV & RM services, IQVIA Life science data, especially safety data, is exploding. It is estimated that pharmaceutical data is increasing at a rate of 36% annually. This is more than other data-driven industries including finance (26% YoY) and manufacturing (30% YoY). This increase is in part due to digital […]
ADVERTISEMENT
ADVERTISEMENT
In Depth 18 Apr 2023
Gene therapy: a powerful tool for hemophilia B?
The approval of HEMGENIX, the first-ever gene therapy for hemophilia B, by the U.S. Food and Drug Administration (FDA) followed by the European Commission, has been momentous in rare disease therapeutic research, paving the way for various gene therapies that are currently being studied. As we observed World Hemophilia Day on April 17, let us […]
News and Trends 18 Apr 2023
Complement Therapeutics raises €72M for eye condition gene therapy
Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement mediated diseases, has completed a €72 million ($78.7 million) Series A financing. The round was led by Gimv, a Belgian-based private equity and venture capital fund, co-led by Forbion as existing investor and further joined by BioGeneration Ventures (BGV), Panakes Partners, […]
News and Trends 17 Apr 2023
Swedish bacterial resistance study could pave road to new antibiotics
A species of ordinary gut bacteria flourishes when the intestinal flora is knocked out by a course of antibiotics. Since the bacteria are naturally resistant to many antibiotics, this can cause problems. A study at Lund University in Sweden now shows how two molecular mechanisms can work together to make the bacterium extra resistant. “Using […]
News and Trends 17 Apr 2023
Aer Therapeutics raises $36M to tackle lung diseases
Aer Therapeutics, a joint University College Dublin (UCD) and University of California, San Francisco (UCSF) biopharmaceutical spin-out company developing novel inhaled treatments for muco-obstructive lung diseases, has announced the closing of a $36 million Series A financing round.Funding was received from a syndicate of premier life science industry investors, including Canaan, OrbiMed, and Hatteras Venture […]
News and Trends 17 Apr 2023
Ghana becomes first country to approve University of Oxford malaria vaccine
Ghana has granted full national licensure for the University of Oxford’s R21/Matrix-M malaria vaccine, marking the first regulatory clearance for the vaccine for use in any country. Developed by the University of Oxford, leveraging Novavax’s adjuvant technology, and manufactured and scaled up by the Serum Institute of India PvT Ltd (SIIPL), the vaccine has been […]
In Depth 14 Apr 2023
mRNA vaccines: a promising future
In 1978, nearly two decades after the discovery of messenger RNA (mRNA), the concept of a vaccine made from mRNA was materialized. Like its name suggests, mRNAs are messengers that aid in decoding genetic information from DNA to synthesize proteins, a key cellular function. Previous attempts at developing a vaccine using mRNA failed because mRNA […]
ADVERTISEMENT
